Versiti Blood Health
15
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.7%
1 terminated/withdrawn out of 15 trials
92.9%
+6.4% vs industry average
13%
2 trials in Phase 3/4
54%
7 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction
Role: lead
Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
Role: collaborator
Microvascular Blood Flow in Sickle Cell Anemia
Role: lead
Strategies to Reduce Iron Deficiency
Role: collaborator
Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)
Role: collaborator
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Role: collaborator
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
Role: collaborator
Bone Density in Voluntary Apheresis Blood Donors
Role: lead
Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection
Role: collaborator
Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation
Role: collaborator
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Role: collaborator
The Von Willebrand Disease (VWD) International Prophylaxis Study
Role: collaborator
Hemoglobin and Iron Recovery Study
Role: collaborator
Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors
Role: collaborator
Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors
Role: collaborator
All 15 trials loaded